Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21713199 | 1.00 | TSHR (0.40) | TSHRCA2ALDH1A1TP53EPHX2 | |
| SCHEMBL13922207 | 1.00 | TSHR (0.40) | TSHRCA2ALDH1A1TP53EPHX2 | |
| SCHEMBL28603730 | 1.00 | TSHR (0.40) | TSHRCA2ALDH1A1TP53EPHX2 | |
| SCHEMBL6246216 | 1.00 | TSHR (0.40) | TSHRCA2ALDH1A1TP53EPHX2 | |
| SCHEMBL11708766 | 0.87 | TSHR (0.43) | TSHRALDH1A1TP53 | |
| SCHEMBL25841567 | 0.86 | ALDH1A1 (0.44) | TSHRCA2ALDH1A1TP53EPHX2 | |
| SCHEMBL56801 | 0.85 | — | — | |
| SCHEMBL28616847 | 0.83 | ALDH1A1 (0.50) | TSHRCA2ALDH1A1TP53EPHX2 | |
| SCHEMBL31665165 | 0.82 | TSHR (0.50) | TSHRALDH1A1TP53 | |
| SCHEMBL13863435 | 0.81 | ADRA2A (0.41) | TSHRCA2ALDH1A1TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3801553-B1 | PRODRUGS OF FULVESTRANT | KASHIV BIOSCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3762386-B1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20220056033-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11124515-B2 | Adenosine receptor antagonists and uses thereof | TEON THERAPEUTICS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | KI PHARMACEUTICALS, LLC | 2021-08-19 | — | — | US | disclosed |
| US-20210163483-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| EP-3801553-A2 | PRODRUGS OF FULVESTRANT | Kashiv Biosciences, LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210040097-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. | 2021-02-11 | — | — | US | disclosed |
| WO-2019173380-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
| US-4152526-A | N-acyl derivatives of 3-amino-2,4,6-triiodobenzoic acid | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1979-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163483-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | ADORA2A, ADORA2B, ADORA3 | TSHR 209/4885CA2 1913/4885ALDH1A1 817/4885 |
| US-20220056033-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | ADORA2A, ADORA2B, ADORA3 | TSHR 209/4885CA2 1913/4885ALDH1A1 817/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | TSHR 543/4885CA2 4583/4885ALDH1A1 2172/4885 |
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | CYP19A1, PGR, CYP21A2 | TSHR 1283/4885CA2 2363/4885ALDH1A1 746/4885 |
| US-11124515-B2 | Adenosine receptor antagonists and uses thereof | ADORA2B, ADORA2A, ADORA3 | TSHR 218/4885CA2 1988/4885ALDH1A1 634/4885 |
| US-20210040097-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | ADORA2A, ADORA2B, ADORA3 | TSHR 209/4885CA2 1913/4885ALDH1A1 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.